Gradient

Senior Scientists

Julie E. Goodman, Ph.D., DABT, FACE, ATS
Email VCard Bio

Education

Ph.D., Toxicology, Johns Hopkins University

Sc.M., Epidemiology, Johns Hopkins University

S.B., Environmental Engineering, Massachusetts Institute of Technology

Diplomate of the American Board of Toxicology

Fellow, American College of Epidemiology (FACE)

Fellow, Academy of Toxicological Sciences (ATS)

Expertise

  • Epidemiology
  • Toxicology
  • Risk Assessment
  • Product Safety
  • Carcinogenesis

Julie E. Goodman, Ph.D., DABT, FACE, ATS

Principal

Email VCard Bio

Dr. Goodman is an expert in toxicology, epidemiology, and assessing human health risks from chemicals in consumer products and the environment.  Her primary responsibilities at Gradient include the analysis and interpretation of epidemiology and toxicity evidence, apparent disease clusters, and chemical exposures.  Before joining Gradient, Dr. Goodman was a Cancer Prevention Fellow at the National Cancer Institute.  She has authored original research articles, review articles, and book chapters on a wide variety of topics, including weight-of-evidence analyses of several chemicals.  She has presented scientific findings and analyses to community groups and regulatory and legislative bodies.  Dr. Goodman is currently an adjunct faculty member in the Department of Epidemiology at the Harvard T. H. Chan School of Public Health. 

Education

Ph.D., Toxicology, Johns Hopkins University

Sc.M., Epidemiology, Johns Hopkins University

S.B., Environmental Engineering, Massachusetts Institute of Technology

Diplomate of the American Board of Toxicology

Fellow, American College of Epidemiology (FACE)

Fellow, Academy of Toxicological Sciences (ATS)

Expertise

  • Epidemiology
  • Toxicology
  • Risk Assessment
  • Product Safety
  • Carcinogenesis

Services

Representative Projects

Cancer Cluster Analysis:  At the request of a municipality and in response to citizens’ concerns, investigated whether there was an increased incidence rate of cancer in residents living near a municipal landfill.  Communicated findings to city officials and residents at public meetings.

Cross-Sectional Study:  Modeled trichloroethylene and perchloroethylene exposure from drinking water and showering.  Used questionnaire data on disease status and other population characteristics to assess the association between exposures and disease rates in a community living near a Superfund site.

Efficacy and Toxicity Analysis:  For a pharmaceutical company, performed an independent analysis of efficacy and toxicity data to determine whether claims in a patent could be challenged.

Regulatory Comment:  Provided written and oral comments to the Clean Air Scientific Advisory Committee (CASAC) on clinical, epidemiology, toxicity, and mode-of-action studies and their bearing on US EPA’s development of National Ambient Air Quality Standards (NAAQS) for ozone, particulate matter, nitrogen oxides, and sulfur oxides.

Weight-of-Evidence Analysis:  Conducted a comprehensive critical weight-of-evidence review of studies bearing on the ability of very low exposures to bisphenol A to affect reproduction and development via endocrine disruption.  Testified before several state legislative committees regarding potential restrictions on bisphenol A.

Benchmark Dose Calculations:  Analyzed US EPA’s use of the lower confidence limit on the BMD1 (BMDL1) to determine a point of departure for cancer risk of dimethylarsenic acid in humans in a white paper submitted to US EPA.

Product Safety Analysis:  Determined whether a toxicological evaluation of a toy was sufficient for determining children's health risks.  Conducted an independent analysis of potential routes of exposure to and toxicity of a chemical found in the toy.

Meta-Analysis:  Conducted meta-analyses and meta-regressions of airway hyper-responsiveness data from clinical studies of asthmatic volunteers exposed to NO2 while exercising or at rest.

Selected Publications

Goodman, JE; Peterson, MK; Hixon, ML; Pacheco Shubin, S.  2017. "Derivation of an oral maximum allowable dose level for bisphenol A." Regul. Toxicol. Pharmacol. 86 : 312-318.

Hoffmann, S; de Vries, RBM; Stephens, ML; Beck, NB; Dirven, HAAM; Fowle, JR III; Goodman, JE; Hartung, T; Kimber, I; Lalu, MM; Thayer, K; Whaley, P; Wikoff, D; Tsaioun, K.  2017. "A primer on systematic reviews in toxicology." Arch. Toxicol. 91 : 2551-2575.

Lynch, HN; Loftus, CT; Cohen, JM; Kerper, LE; Kennedy, EM; Goodman, JE.  2016. "Weight-of-evidence evaluation of associations between particulate matter exposure and biomarkers of lung cancer." Regul. Toxicol. Pharmacol. 82 : 53-93.